ImmunoQure AG and Memo Therapeutics AG announce collaboration for the production of APS-1 cognate, paired libraries

ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases today announced the publication of data in the leading scientific journal Frontiers in Immunology.

ImmunoQure AG announces publication in leading scientific journal of findings that demonstrate autoantibody responses against multiple proteins in APECED/APS-1 patients

ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases today announced the publication of data in the leading scientific journal Frontiers in Immunology.

Servier and ImmunoQure AG enter into strategic partnership for the development of an Interferon-α human autoantibody

ImmunoQure, a biotech company focused on the research and development of human autoantibodies as therapeutics for the treatment of common human diseases and the international pharmaceutical company Servier today announced the establishment of a Worldwide, exclusive partnership for the development of a therapeutic autoantibody neutralizing interferon- α.

ImmunoQure enables the establishment of Sardinian patient support group

ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today welcomed the establishment of a non-profit charity for APS-1/APECED patients who live in Sardinia.

ImmunoQure AG announces publication of findings that advance it’s Interferon program in the journal Arthritis & Rheumatology

ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the journal Arthritis & Rheumatology.

ImmunoQure AG announces publication in leading scientific journal of findings that enable companion diagnostic development for Interferon program

ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal The Journal of Experimental Medicine. In a Worlds-first, the authors have developed a system by which interferon-α (IFNα) levels can be measured in serum, plasma and cerebrospinal fluid.

ImmunoQure AG Announces Publication in Cell of Naturally Occurring Patient-Derived Autoantibodies That Limit Human Diseases

ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal Cell, demonstrating that such therapeutics can limit a variety of common human diseases.